

Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies

Supplementary Materials

Supplementary Table S1: Areas under the ROC curve for assessing combinations of miRNAs for discriminating between malignant and non-malignant pancreatic EUS-FNAs

	miR-21	miR-10b	miR-155	miR-196a	miR-210	miR-135b/24
miR-21		0.841 (0.731–0.952)	0.930 (0.868–0.992)	0.873 (0.778–0.968)	0.852 (0.752–0.952)	0.837 (0.729–0.945)
miR-10b			0.926 (0.858–0.994)	0.837 (0.728–0.947)	0.831 (0.716–0.945)	0.820 (0.704–0.936)
miR-155				0.873 (0.778–0.968)	0.872 (0.775–0.968)	0.877 (0.782–0.972)
miR-196a					0.778 (0.658–0.898)	0.772 (0.648–0.897)
miR-210						0.790 (0.672–0.907)
miR-135b/24						

AUC (95% CI).

Supplementary Table S2: Demographic and clinical description of validation EUS-FNA and FFPE cohorts

	Validation EUS-FNAs			Validation FFPE		
	Benign/ Inflammatory/ Pseudocyst (<i>n</i> = 3)	PDAC (<i>n</i> = 7)	<i>P</i>	Benign (IPMN, <i>n</i> = 5)	Malignant (CEI, <i>n</i> = 5; PDAC (<i>n</i> = 6)	<i>P</i>
Age (years)	50.4 ± 26.7	70.3 ± 9.3	0.102†	64.0 ± 9.7	71.8 ± 7.5	0.095†
Female gender (%)	2 (66.7%)	3 (42.9%)	0.490☼	4 (80%)	3 (27.3%)	0.049 ☼
Symptoms	3 (100%)	7 (100%)	NS☼	3 (60%)	8 (72.2%)	0.611☼
Size (mm)	22.3 ± 7.5	28.6 ± 7.5	0.262†	24 ± 9.1	32.8 ± 8.5	0.074†
Solid or cystic	1/2	7/0	0.016 ☼	1/4	9/2	0.018 ☼
No. of fine needle passes	1.7 ± 0.6	3.0 ± 0.6	0.010 †	1.6 ± 0.5	2.3 ± 0.6	0.061†
RNA yield (ng/μl)	274.1 ± 210.4	59.8 ± 70.3	0.033 †	258.7 ± 179.0	248.1 ± 135.9	0.895†

PDAC, Pancreatic Ductal Adenocarcinoma; IPMN, intraductal papillary mucinous neoplasm; CEI, Carcinoma-ex-IPMN.
 ☼Chi-square test. †Unpaired *t*-test. NS, non-significant.